Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Total Debt (2016 - 2025)

Gsk has reported Total Debt over the past 10 years, most recently at $23.6 billion for Q4 2025.

  • Quarterly results put Total Debt at $23.6 billion for Q4 2025, up 8.3% from a year ago — trailing twelve months through Dec 2025 was $23.6 billion (up 8.3% YoY), and the annual figure for FY2025 was $23.6 billion, up 8.3%.
  • Total Debt for Q4 2025 was $23.6 billion at Gsk, up from $21.8 billion in the prior quarter.
  • Over the last five years, Total Debt for GLAXF hit a ceiling of $29.1 billion in Q4 2021 and a floor of $21.5 billion in Q4 2022.
  • Median Total Debt over the past 5 years was $22.3 billion (2023), compared with a mean of $23.6 billion.
  • Biggest five-year swings in Total Debt: decreased 26.04% in 2022 and later increased 8.3% in 2025.
  • Gsk's Total Debt stood at $29.1 billion in 2021, then decreased by 26.04% to $21.5 billion in 2022, then rose by 3.97% to $22.3 billion in 2023, then fell by 2.65% to $21.8 billion in 2024, then grew by 8.3% to $23.6 billion in 2025.
  • The last three reported values for Total Debt were $23.6 billion (Q4 2025), $21.8 billion (Q4 2024), and $22.3 billion (Q4 2023) per Business Quant data.